ArticleEndoscopic ultrasound
Utility of archived EUS-guided fine-needle biopsy samples for next-generation sequencing in pancreatic adenocarcinoma.
Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Comprehensive molecular profiling with next-generation sequencing (NGS) may enable personalized therapies, but its feasibility using EUS-guided fine-needle biopsy (EUS-guided FNB) and broad panels in routine practice remains unclear. This study aimed to assess the feasibility of NGS using residual diagnostic tissue from EUS-guided FNB in PDAC, without dedicated sampling. Methods: We performed a retrospective single-center study of patients with PDAC who underwent EUS-guided FNB, analyzing residual paraffin-embedded tissue blocks for NGS using a 63-gene panel. Samples required a minimum tumor cellularity of 20% and tumor area ≥10 mm Results: Thirty-five patients were included. NGS was successful in 74.3% of cases (26/35) using residual diagnostic material without additional biopsy passes. No significant baseline or procedural differences were observed between groups, except for metastatic disease, which was more frequent in the NGS-unfeasible group (55.6% Conclusion: EUS-guided FNB samples can support NGS from residual diagnostic tissue with high feasibility, avoiding dedicated sampling. This pragmatic approach may streamline molecular profiling and expand access to precision oncology in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.